Daiwa Securities Group
PRLD icon

Daiwa Securities Group’s Prelude Therapeutics PRLD Stock Holding History

Daiwa Securities Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-104
Closed – – 1378
2023
Q3 		$0 Hold
104
– – ﹤0.01% 1328
2023
Q2 		$0 Hold
104
– – ﹤0.01% 1345
2023
Q1 		$1K Hold
104
– – ﹤0.01% 1277
2022
Q4 		$1K Hold
104
– – ﹤0.01% 1289
2022
Q3 		$1K Hold
104
– – ﹤0.01% 1308
2022
Q2 		$1K Hold
104
– – ﹤0.01% 1314
2022
Q1 		$1K Hold
104
– – ﹤0.01% 1330
2021
Q4 		$1K Buy
+104
New +$1.69K ﹤0.01% 1351

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Daiwa Securities Group's PRLD Position: Q4 2023 in Review

Daiwa Securities Group sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 104 shares.

Daiwa Securities Group first reported a position in PRLD in Q4 2021 and held it in 8 quarters. The position peaked at $1K in Q1 2023. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

  • Daiwa Securities Group reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 104 Prelude Therapeutics shares in Q4 2023.
  • Daiwa Securities Group first reported a position in Prelude Therapeutics in Q4 2021 and held it in 8 quarters.
  • Daiwa Securities Group's Prelude Therapeutics position peaked at $1K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.